GI INNOVATION
June 17, 2025
Company Presentation
Oncology
153A
GI Innovation, a KOSDAQ-listed biotech, pioneers fusion protein drugs for cancer and allergies. Since 2017, it secured $230 million through funding rounds, IPO, and licensing deals for preclinical and clinical assets. Leveraging global partnerships for rapid development, the leading programs include immuno-oncology assets GI-101, subcutaneous form GI-102, and anti-allergy asset GI-301, alongside other innovative programs, which includes metabolic immuno-oncology asset GI-108
Company HQ City:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
GI-102, GI-101A
CEO
Byunggeon Rhee, Junho Hong
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3
Exchange
KOSDAQ
Ticker
A358570
When you expect your next catalyst update?
Licensing out
What is your next catalyst (value inflection) update?
first half of this year
Website
https://www.gi-innovation.com/en/
Primary Speaker
)
)
){kind=logo}
){kind=logo}
){kind=logo}